The effect of sucroferric oxyhydroxide starting from a small amount
Not Applicable
- Conditions
- Chronic renal failure
- Registration Number
- JPRN-UMIN000034640
- Lead Sponsor
- Saitama Tsukinomori Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients complicated with serious diseases such as cancer, hematological disorders, and liver cirrhosis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The prevalence of side effects of sucroferric oxyhydroxide and the transition of serum phosphorus level
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sucroferric oxyhydroxide's effect on phosphate metabolism in JPRN-UMIN000034640 chronic renal failure patients?
How does low-dose sucroferric oxyhydroxide compare to standard phosphate binders in managing hyperphosphatemia for CKD patients in JPRN-UMIN000034640?
Which biomarkers correlate with response to sucroferric oxyhydroxide in JPRN-UMIN000034640 observational study of chronic renal failure patients?
What adverse events are reported with sucroferric oxyhydroxide in JPRN-UMIN000034640 and how are they managed in CKD patients?
Are there combination therapies with sucroferric oxyhydroxide and other CKD treatments that improve outcomes in JPRN-UMIN000034640 patients?